Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Among older adults receiving CAR-T therapy, 5.8% experienced major adverse cardiovascular events (MACE), associated with increased mortality. Pre-existing cardiac conditions heightened risk, underscoring the need for cardiovascular monitori
A retrospective study demonstrates the safety and efficacy of GCSF and plerixafor for CD34+ stem cell mobilization as autologous backup in sickle cell patients undergoing alternate donor HSCT, with insights relevant for gene therapy.
This phase II study evaluates the all-oral ixazomib-pomalidomide-dexamethasone regimen in triple-class exposed relapsed/refractory multiple myeloma patients, demonstrating promising efficacy and manageable safety in an elderly and high-risk
Long-term phase 1 data confirm asciminib’s efficacy and safety in treating CML-CP patients harboring the resistant BCR::ABL1 T315I mutation, with sustained major molecular responses and manageable adverse events over nearly six years.
This article explores how type-I interferon activates NK cells to control polycythemia vera progression, revealing insights into immune modulation and therapeutic potential in myeloproliferative neoplasms.
A phase II trial demonstrates the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning in AML patients aged 40-65, showing high leukemia-free survival and low toxicity, supporting its use over busulfan r
This study reveals early establishment of a diverse naïve B-cell receptor repertoire within 3 months post-pediatric HSCT, followed by gradual antigen-experienced maturation over 24 months, reflecting physiological B-cell development and sup
Bendamustine monotherapy achieved high response rates and inhibited STAT3 signaling in patients with high burden T-cell large granular lymphocytic leukemia, showing promise as an effective and well-tolerated treatment option.
This study develops a high-content ex vivo assay of T cell dynamics to predict multiple myeloma patient response to bispecific T cell engager therapies, offering a novel functional biomarker for therapy stratification.
A phase 1 trial of XmAb18968, a CD38-CD3 bispecific antibody, demonstrates safety and encouraging efficacy in heavily pretreated relapsed/refractory AML and T-ALL patients, highlighting a novel therapeutic avenue.
Lisocabtagene maraleucel demonstrates durable five-year survival and potential cure in relapsed/refractory large B-cell lymphoma, with manageable long-term safety, based on data from the TRANSCEND NHL 001 trial and its long-term follow-up.
Single-cell transcriptomic profiling of ide-cel CAR-T products reveals that intrinsic NF-κB signaling in CD4 CAR-T cells correlates with durable remission in relapsed/refractory multiple myeloma, marking T-cell fitness and potential therape
This study reveals the population prevalence and incident risk of HPA-1a alloimmunisation in pregnancy across diverse ethnic groups, highlighting its rarity and establishing a framework for risk assessment in foetal-neonatal alloimmune thro
In AML patients undergoing unrelated donor allo-HCT with intermediate-intensity conditioning, ATG-based GvHD prophylaxis demonstrated better overall and leukemia-free survival and reduced relapse compared to alemtuzumab, despite higher acut
A large registry analysis supports post-transplant cyclophosphamide (PTCy) as an effective alternative to anti-thymocyte globulin (ATG) for preventing graft-versus-host disease (GVHD) in reduced-intensity conditioning matched donor peripher
This review synthesizes current evidence on germline lymphoma-predisposing variants, highlighting their impact on earlier cancer onset and variable survival rates in pediatric lymphoma patients, underscoring implications for genetic screeni
This international cohort study evaluates the effectiveness of CHOEP/EPOCH versus CHOP chemotherapy in aggressive adult T-cell leukemia/lymphoma, revealing subtype-specific survival benefits in lymphomatous ATL but inconclusive results in a
This article explores how cohesin mutations impair HLA-class II gene expression, contributing to leukemic progression from transient abnormal myelopoiesis to myeloid leukemia in children with Down syndrome.
This study evaluates the outcomes and critical factors influencing the success of tisagenlecleucel therapy for children and young adults with B-cell acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplant across Euro
Loss of FAP-1 disrupts megakaryocyte membrane development and platelet function through aberrant Src activation, leading to myelofibrosis-like pathology with potential therapeutic targeting by Src inhibition.
Open language-specific specialty feeds and department pages.